For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the arrival of Tafamidis and the formulated version represents a genuine change. These novel therapies preserve the transthyretin protein, preventing its destructive build-up and lessening the severity of the condition . People are now reporting improv